Olga Ivanova

Ms. Olga Ivanova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
OIOlga Ivanova
Olga Ivanova
KAKsenia S. Anufrieva
Ksenia S. Anufrieva
AKAnastasia N. Kazakova
Anastasia N. Kazakova
IMIrina K. Malyants
Irina K. Malyants
PSPolina V. Shnaider
Polina V. Shnaider
VSVictoria O. Shender
Victoria O. Shender
Dysregulation of pre-mRNA splicing is a common hallmark of cancer cells and it is associated with altered expression, localization, and mutations of the components of the splicing machinery. In the last few years, it has been elucidated that spliceosome components can also influence cellular processes in a splicing-independent manner. Here, we analyze open source data to understand the effect of the knockdown of splicing factors in human cells on the expression and splicing of genes relevant to cell proliferation, migration, cell cycle regulation, DNA repair, and cell death. We supplement this information with a comprehensive literature review of non-canonical functions of splicing factors linked to cancer progression. We also specifically discuss the involvement of splicing factors in intercellular communication and known autoregulatory mechanisms in restoring their levels in cells. Finally, we discuss strategies to target components of the spliceosome machinery that are promising for anticancer therapy. Altogether, this review greatly expands understanding of the role of spliceosome proteins in cancer progression.

Verified
Journal Article
Open access
PDF file
PSPolina V. Shnaider
Polina V. Shnaider
OIOlga Ivanova
Olga Ivanova
IMIrina Malyants
Irina Malyants
KAKsenia S. Anufrieva
Ksenia S. Anufrieva
ISIlya A. Semenov
Ilya A. Semenov
VSVictoria O. Shender
Victoria O. Shender
The malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. However, remaining cancer cells may rapidly reestablish the tumor after a temporary remission. These new populations of malignant cells usually have increased resistance not only to the first-line agent, but also to the second- and third-line drugs, leading to a significant decrease in patient survival. Multiple studies describe the mechanism of acquired therapy resistance. In past decades, it became clear that, in addition to the simple selection of pre-existing resistant clones, therapy induces a highly complicated and tightly regulated molecular response that allows tumors to adapt to current and even subsequent therapeutic interventions. This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy. Moreover, we describe less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Understanding these molecular mechanisms will be beneficial in finding novel therapeutic approaches for cancer therapy.

19 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVictoria O. Shender
Victoria O. Shender
KAKsenia S. Anufrieva
Ksenia S. Anufrieva
PSPolina V. Shnaider
Polina V. Shnaider
GAGeorgij Arapidi
Georgij Arapidi
MPMarat Pavlyukov
Marat Pavlyukov
VGVadim Govorun
Vadim Govorun
Ovarian cancer often develops resistance to conventional therapies, hampering their effectiveness. Here, using ex vivo paired ovarian cancer ascites obtained before and after chemotherapy and in vitro therapy-induced secretomes, we show that molecules secreted by ovarian cancer cells upon therapy promote cisplatin resistance and enhance DNA damage repair in recipient cancer cells. Even a short-term incubation of chemonaive ovarian cancer cells with therapy-induced secretomes induces changes resembling those that are observed in chemoresistant patient-derived tumor cells after long-term therapy. Using integrative omics techniques, we find that both ex vivo and in vitro therapy-induced secretomes are enriched with spliceosomal components, which relocalize from the nucleus to the cytoplasm and subsequently into the extracellular vesicles upon treatment. We demonstrate that these molecules substantially contribute to the phenotypic effects of therapy-induced secretomes. Thus, SNU13 and SYNCRIP spliceosomal proteins promote therapy resistance, while the exogenous U12 and U6atac snRNAs stimulate tumor growth. These findings demonstrate the significance of spliceosomal network perturbation during therapy and further highlight that extracellular signaling might be a key factor contributing to the emergence of ovarian cancer therapy resistance.

31 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVictoria O. Shender
Victoria O. Shender
KAKsenia S. Anufrieva
Ksenia S. Anufrieva
PSPolina V. Shnaider
Polina V. Shnaider
GAGeorgij Arapidi
Georgij Arapidi
MPMarat Pavlyukov
Marat Pavlyukov
VGVadim Govorun
Vadim Govorun

14 May 2021 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
VSVictoria O. Shender
Victoria O. Shender
PSPolina V. Shnaider
Polina V. Shnaider
KAKsenia Anufrieva
Ksenia Anufrieva
OIOlga Ivanova
Olga Ivanova
GAGeorgij Arapidi
Georgij Arapidi
VGVadim Govorun
Vadim Govorun
The relapse rate of ovarian cancer patients is about 85% with progression‐free survival time less than two years. Cisplatin resistance of ovarian cancer cells cannot be explained only by mutations in DNA repair genes and increased expression of multidrug resistance proteins [Heijink et al., 2019]. It has been recently shown that cancer cells subjected to chemotherapy can secrete signaling molecules into the extracellular medium that contribute to the survival of neighboring tumor cells [Obenauf et al., 2015, Pavlyukov et al., 2018]. Thus, it is extremely important to take into account the role of intercellular signaling that occurs during therapy. In this study, we performed a comprehensive analysis of changes in secretomes of ovarian cancer cells under chemotherapy condition and demonstrated a new molecular mechanism for the acquisition of a more aggressive tumor phenotype. In addition to in vitro secretomes, we analyzed paired ascitic fluids from the same ovarian cancer patients before and after neoadjuvant chemotherapy (n = 10). We have shown that ascitic fluids after chemotherapy, as well as in vitro therapy‐induced secretomes, contain components that contribute significantly to the formation of mesenchymal phenotype of primary cancer cell cultures, which was accompanied by increased migration and resistance to chemotherapy of intact tumor cells. Comprehensive proteomic analysis of secretomes and ascites revealed that extracellular fluids after chemotherapy are enriched with spliceosomal components. In addition, using fluorescence labelling and modified SILAC technology, we demonstrated the possibility of spliceosomal protein transport by extracellular vesicles from dying tumor cells to recipient cells. We suggest that splicing factors circulating in the extracellular space can “prepare” intact cancer cells for subsequent drug treatment. Therefore, combination of platinum‐based drugs with spliceosomal inhibitors could improve the survival of patients with ovarian cancer.

Verified
Journal Article
Open access
PDF file
PSPolina V. Shnaider
Polina V. Shnaider
IMIrina Malyants
Irina Malyants
OIOlga Ivanova
Olga Ivanova
VGVeronika S. Gordeeva
Veronika S. Gordeeva
ESEkaterina A. Svirina
Ekaterina A. Svirina
VSVictoria O. Shender
Victoria O. Shender
High-grade serous ovarian carcinoma (HGSOC) remains the most common and deadly form of ovarian cancer. However, available cell lines usually fail to appropriately represent its complex molecular and histological features. To overcome this drawback, we established OVAR79, a new cell line derived from the ascitic fluid of a patient with a diagnosis of HGSOC, which adds a unique set of properties to the study of ovarian cancer. In contrast to the common models, OVAR79 expresses TP53 without the common hotspot mutations and harbors the rare combination of mutations in both PIK3CA and PTEN genes, together with high-grade chromosomal instability with multiple gains and losses. These features, together with the high proliferation rate, ease of cultivation, and exceptional transfection efficiency of OVAR79, make it a readily available and versatile tool for various studies in the laboratory. We extensively characterized its growth, migration, and sensitivity to platinum- and taxane-based treatments in comparison with the commonly used SKOV3 and OVCAR3 ovarian cell lines. In summary, OVAR79 is an excellent addition for basic and translational ovarian cancer research and offers new insights into the biology of HGSOC.